Business Wire

CA-EXPERIAN

25.1.2024 12:01:32 CET | Business Wire | Press release

Share
The Sophistication of Cybercriminals Intensifies With Emerging Strategies for Cashing in or Causing Chaos

While tried and true tactics like phishing and malware are here to stay, there are always new approaches to watch out for in the cybersecurity space. Experian’s 11th annual Data Breach Industry Forecast includes six predictions for 2024 that focus a global lens on what savvy moves cybercriminals from near and far will potentially make to penetrate organizations and reap rewards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125797127/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

To download the Experian Data Breach Resolution Industry Forecast, go to https://ex.pn/2024databreachindustryforecast. (Graphic: Experian)

While 2023 was a “successful” year for bad actors, we may see the following emerge to shake up the cyber landscape even more this year:

  • Six Degrees of Separation: There’s no question third-party data breaches have made headlines. With increased data collection, storage and movement there are plenty of partners down the supply chain that could be targeted. We predict attacks on systems four, five or six degrees from the original source as vendors outsource data and technology solutions who outsource to another expert and so on.
  • Little by Little Becomes A lot: When trying to achieve a goal, it’s said that taking small steps can lead to big results. Hackers could apply that same rule. Instead of making drastic moves and trying to reap instant reward such as with ransomware, bad actors may just manipulate or alter the tiniest bits of data to stay under the radar such as changing a currency rate or adjusting the coordinates for transportation, which can have a major impact.
  • Not a Third Wheel: It’s widely known who the major players are globally that sponsor attacks and a new country in South Asia may join the international stage with their large population of engineers and programmers. While reportedly having been in the game focusing cyberattacks regionally due to political tensions, this country may broaden their sights in the future.
  • No, not Mother Earth!: Plutonium, terbium, silicon wafers — these rare earth materials that are the building blocks for today’s hardware are rapidly becoming the most sought-after resources on the planet. Any disruption to an already strained supply chain could send the industry (and the economy that relies on these materials) spinning. This presents an intriguing opportunity for hackers looking to create disruption, or nation-states wanting to corner a market or disrupt an enemy’s economy.
  • The Scarface Effect: Like drug cartels, cybergangs are forming sophisticated organizations as joining like-minded actors can be incredibly advantageous. This spans globally with countries potentially helping each other to advance common goals and interests. We’ll see more hackers for trade, crews looking to expand their monopolies, and cyberwarfare alliances.
  • Winning from the Inside: In 2024, we may see enterprising threat actors target more publicly traded companies to gain insights to cheat the stock market or plan their attacks and sell their stash before value nosedives. Rather than breach an organization and play in the underground with stolen data, threat actors could leverage data extraction and their talents in plain sight as everyday investors.

“Cybercriminals are continually working smarter not harder,” said Michael Bruemmer, vice president, Global Data Breach Resolution at Experian. “They are leveraging new technologies like artificial intelligence and applying their talents in different ways to be more strategic and stay a step ahead. Organizations should not ignore even the slightest security abnormalities and be more aware of what global interests may make them a target.”

To access the complimentary report, visit https://ex.pn/2024databreachindustryforecast.

“Today, perpetrators can come from anywhere in the world and bring with them robust resources and expertise,” added Jim Steven, Head of Crisis and Data Response Services at Experian Global Data Breach Resolution in the United Kingdom. “There are many global crime syndicates and nation-backed operations, so companies need to invest in sophisticated prevention and response methods to protect themselves.”

Experian Global Data Breach Resolution offers international resources for companies impacted by a security incident and services include IdentityWorks℠ Global, multilingual call centers, and notifications covering more than 100 countries. Experian has also recently expanded capabilities to Japan, Taiwan and Thailand.

To learn more about Experian Global Data Breach Resolution, go to https://www.experian.com/business/solutions/fraud-management/global-data-breach-services.

About Experian

Experian is the world’s leading global information services company. During life’s big moments – from buying a home or a car, to sending a child to college, to growing a business by connecting with new customers – we empower consumers and our clients to manage their data with confidence. We help individuals to take financial control and access financial services, businesses to make smarter decisions and thrive, lenders to lend more responsibly, and organizations to prevent identity fraud and crime.

We have 22,000 people operating across 32 countries and every day we’re investing in new technologies, talented people, and innovation to help all our clients maximize every opportunity. With corporate headquarters in Dublin, Ireland, we are listed on the London Stock Exchange (EXPN) and are a constituent of the FTSE 100 Index.

Learn more at www.experianplc.com or visit our global content hub at our global news blog for the latest news and insights from the Group.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240125797127/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye